Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 158

1.

JNK regulates muscle remodeling via myostatin/SMAD inhibition.

Lessard SJ, MacDonald TL, Pathak P, Han MS, Coffey VG, Edge J, Rivas DA, Hirshman MF, Davis RJ, Goodyear LJ.

Nat Commun. 2018 Aug 2;9(1):3030. doi: 10.1038/s41467-018-05439-3.

2.

Subcutaneous and Visceral Adipose Tissue Secretions from Extremely Obese Men and Women both Acutely Suppress Muscle Insulin Signaling.

Sarr O, Strohm RJ, MacDonald TL, Gaudio N, Reed JK, Foute-Nelong J, Dyck DJ, Mutch DM.

Int J Mol Sci. 2017 May 2;18(5). pii: E959. doi: 10.3390/ijms18050959.

3.

Estradiol does not directly regulate adipose lipolysis.

MacDonald TL, MacPherson R, Castellani L, Cervone D, Anderson E, Wright DC, Dyck DJ.

Adipocyte. 2017 Apr 3;6(2):76-86. doi: 10.1080/21623945.2017.1287638. Epub 2017 Jan 27.

4.

Structural Requirements and Docking Analysis of Amidine-Based Sphingosine Kinase 1 Inhibitors Containing Oxadiazoles.

Houck JD, Dawson TK, Kennedy AJ, Kharel Y, Naimon ND, Field SD, Lynch KR, Macdonald TL.

ACS Med Chem Lett. 2016 Mar 1;7(5):487-92. doi: 10.1021/acsmedchemlett.6b00002. eCollection 2016 May 12.

5.

Synthesis and Antimicrobial Evaluation of Amixicile-Based Inhibitors of the Pyruvate-Ferredoxin Oxidoreductases of Anaerobic Bacteria and Epsilonproteobacteria.

Kennedy AJ, Bruce AM, Gineste C, Ballard TE, Olekhnovich IN, Macdonald TL, Hoffman PS.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3980-7. doi: 10.1128/AAC.00670-16. Print 2016 Jul.

6.

Exercise training is an effective alternative to estrogen supplementation for improving glucose homeostasis in ovariectomized rats.

MacDonald TL, Ritchie KL, Davies S, Hamilton MJ, Cervone DT, Dyck DJ.

Physiol Rep. 2015 Nov;3(11). pii: e12617. doi: 10.14814/phy2.12617. Epub 2015 Nov 24.

7.

Feeding butter with elevated content of trans-10, cis-12 conjugated linoleic acid to obese-prone rats impairs glucose and insulin tolerance.

Hamilton M, Hopkins LE, AlZahal O, MacDonald TL, Cervone DT, Wright DC, McBride BW, Dyck DJ.

Lipids Health Dis. 2015 Sep 28;14:119. doi: 10.1186/s12944-015-0122-2.

8.

Preclinical studies of amixicile, a systemic therapeutic developed for treatment of Clostridium difficile infections that also shows efficacy against Helicobacter pylori.

Hoffman PS, Bruce AM, Olekhnovich I, Warren CA, Burgess SL, Hontecillas R, Viladomiu M, Bassaganya-Riera J, Guerrant RL, Macdonald TL.

Antimicrob Agents Chemother. 2014 Aug;58(8):4703-12. doi: 10.1128/AAC.03112-14. Epub 2014 Jun 2.

9.

Adiponectin is sufficient, but not required, for exercise-induced increases in the expression of skeletal muscle mitochondrial enzymes.

Ritchie IR, MacDonald TL, Wright DC, Dyck DJ.

J Physiol. 2014 Jun 15;592(12):2653-65. doi: 10.1113/jphysiol.2014.273680. Epub 2014 Mar 31.

10.

IL-6 and epinephrine have divergent fiber type effects on intramuscular lipolysis.

Macdonald TL, Wan Z, Frendo-Cumbo S, Dyck DJ, Wright DC.

J Appl Physiol (1985). 2013 Nov;115(10):1457-63. doi: 10.1152/japplphysiol.00558.2013. Epub 2013 Sep 19.

11.
12.

A model for the regulation of T-type Ca(2+) channels in proliferation: roles in stem cells and cancer.

Gray LS, Schiff D, Macdonald TL.

Expert Rev Anticancer Ther. 2013 May;13(5):589-95. doi: 10.1586/era.13.34. Review.

PMID:
23617350
13.

Cost-effective and Large-scale synthesis of 16:0 Lysophosphatidic Acid.

East JE, Macdonald TL.

Synth Commun. 2012 Dec 1;42(24):3614-3618. Epub 2012 Aug 20.

14.

Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.

Warren CA, van Opstal E, Ballard TE, Kennedy A, Wang X, Riggins M, Olekhnovich I, Warthan M, Kolling GL, Guerrant RL, Macdonald TL, Hoffman PS.

Antimicrob Agents Chemother. 2012 Aug;56(8):4103-11. doi: 10.1128/AAC.00360-12. Epub 2012 May 14.

15.

Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist.

East JE, Carter KM, Kennedy PC, Schulte NA, Toews ML, Lynch KR, Macdonald TL.

Medchemcomm. 2011 Mar 3;2(4):325-330.

16.

Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate.

Kharel Y, Mathews TP, Gellett AM, Tomsig JL, Kennedy PC, Moyer ML, Macdonald TL, Lynch KR.

Biochem J. 2011 Dec 15;440(3):345-53. doi: 10.1042/BJ20110817.

17.

Characterization of a sphingosine 1-phosphate receptor antagonist prodrug.

Kennedy PC, Zhu R, Huang T, Tomsig JL, Mathews TP, David M, Peyruchaud O, Macdonald TL, Lynch KR.

J Pharmacol Exp Ther. 2011 Sep;338(3):879-89. doi: 10.1124/jpet.111.181552. Epub 2011 Jun 1.

18.

Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells.

Kennedy AJ, Mathews TP, Kharel Y, Field SD, Moyer ML, East JE, Houck JD, Lynch KR, Macdonald TL.

J Med Chem. 2011 May 26;54(10):3524-48. doi: 10.1021/jm2001053. Epub 2011 May 2.

19.

Synthesis and antimicrobial evaluation of nitazoxanide-based analogues: identification of selective and broad spectrum activity.

Ballard TE, Wang X, Olekhnovich I, Koerner T, Seymour C, Salamoun J, Warthan M, Hoffman PS, Macdonald TL.

ChemMedChem. 2011 Feb 7;6(2):362-77. doi: 10.1002/cmdc.201000475. Epub 2010 Dec 29.

20.

A rapid assay for assessment of sphingosine kinase inhibitors and substrates.

Kharel Y, Mathews TP, Kennedy AJ, Houck JD, Macdonald TL, Lynch KR.

Anal Biochem. 2011 Apr 15;411(2):230-5. doi: 10.1016/j.ab.2011.01.003. Epub 2011 Jan 7.

Supplemental Content

Loading ...
Support Center